Drug Profile
Research programme: enzyme replacement therapeutics - Enobia Pharma
Alternative Names: Recombinant PHEX; Soluble PHEX; sPHEX; Targ sPHEX; TNSALP replacement therapyLatest Information Update: 29 Jul 2021
Price :
$50
*
At a glance
- Originator Enobia Pharma
- Class Recombinant proteins
- Mechanism of Action Enzyme replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Osteomalacia; X-linked dominant hypophosphataemic rickets
Most Recent Events
- 21 Jul 2021 Alexion Pharmaceuticals has been acquired by AstraZeneca and changed its name to Alexion AstraZeneca Rare Disease
- 10 Feb 2012 Discontinued - Preclinical for Osteomalacia in Canada (Parenteral)
- 10 Feb 2012 Discontinued - Preclinical for X-linked dominant hypophosphataemic rickets in Canada (Parenteral)